Please assess the completion status of the following clinical trial:

Trial Title: Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: healthy volunteers~* Part 2:~* study will consist of patients presenting to the UCSF interstitial lung disease (ILD) outpatient clinic with imaging indicative of lung fibrosis but of uncertain classification, and who are willing to take EGCG for a minimum of 2 weeks prior to surgery.~Exclusion Criteria:~* co-morbidities affect hepatic function, such as HCV infection, cirrhosis, or~* using drugs with significant hepatic toxicities

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- EGCG PK in healthy volunteers 450 mg (Type: OTHER): Healthy volunteers: 450 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
- EGCG PK in healthy volunteers 600 mg (Type: OTHER): Healthy volunteers: 600 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
- EGCG PK in healthy volunteers 750 mg (Type: OTHER): Healthy volunteers: 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
- No treatment control in ILD patients (Type: NO_INTERVENTION): Patients: not treated with EGCG
- EGCG treatment in ILD patients (Type: EXPERIMENTAL): Patients: 600 mg EGCG capsules once daily by mouth for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).